Novelion Therapeutics Reports First Quarter 2017 Financial Results
May 09, 2017 11:03 am UTC| Business
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer Defined Clinical Development Plan for Zuretinol Following Positive FDA MeetingCompany Reiterates FY 2017 Total Net Revenues Guidance Between...
Novelion Therapeutics Reports First Quarter 2017 Financial Results
May 09, 2017 11:03 am UTC| Business
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer Defined Clinical Development Plan for Zuretinol Following Positive FDA MeetingCompany Reiterates FY 2017 Total Net Revenues Guidance Between...
Novelion Therapeutics Reports First Quarter 2017 Financial Results
May 09, 2017 11:03 am UTC| Business
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer Defined Clinical Development Plan for Zuretinol Following Positive FDA MeetingCompany Reiterates FY 2017 Total Net Revenues Guidance Between...
uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress
May 09, 2017 11:02 am UTC| Business
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 09, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with severe medical needs, today reported its...
uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress
May 09, 2017 11:02 am UTC| Business
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 09, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with severe medical needs, today reported its...
ProQR Announces R&D Day in New York on June 15
May 09, 2017 11:02 am UTC| Business
Key updates: ProQR to host an RD day in New York on June 15 from 8:00am to 1:00pm ETPresentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313...
Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam
May 09, 2017 11:02 am UTC| Business
IV Meloxicam 30mg Continues to Demonstrate Solid Safety and Tolerability Profile Company on Track to File NDA with U.S. FDA in Early Q 3 2017 Recro Completes Largest Phase 3 Double Blind Placebo Controlled Non-Opioid...
Threading Opportunity: How an India–EU FTA Could Reweave Textile Fortunes